YujieZhaoMDPh.D

Oncology • Jacksonville, FL

Consultant, clinical assistant professor

Join to view full profile

Dr. Zhao is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Zhao's full profile

Already have an account?

Office
4500 San Pablo Road S
Jacksonville, FL 32224

Summary

Dr. Yujie Zhao is an oncologist in Jacksonville, FL and is affiliated with multiple hospitals in the area, including Mayo Clinic Hospital in Florida and St. Vincent's Medical Center Southside. She received her medical degree from Beijing Medical University and has been in practice 23 years. She is experienced in Head and Neck cancer, Lung cancer and Thyroid cancer.

Education & Training

Rutgers Health/Robert Wood Johnson Medical SchoolFellowship, Hematology and Medical Oncology, 2008 - 2011
Rutgers Health/Cooperman Barnabas Medical CenterResidency, Internal Medicine, 2005 - 2008
Beijing Medical UniversityClass of 1994

Certifications & Licensure

FL State Medical License 2019 - 2026
IL State Medical License 2015 - 2023
NY State Medical License 2011 - 2017
NJ State Medical License 2008 - 2011

Clinical Trials

Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery Start of enrollment: 2011 Oct 26
Active, not recruiting
Phase 1, Phase 2
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Start of enrollment: 2013 May 08
Completed
Phase 2
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) Start of enrollment: 2014 Mar 27
Completed
Phase 3
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non-small cell lung cancer, and renal cell carcinoma.
Jason J Luke, Georgina V Long, Caroline Robert, Matteo S Carlino, Toni K Choueiri
European Journal of Cancer. 2024-08-01
Sex- and Age-Associated Differences in Genomic Alterations among Patients with Advanced Non-Small Cell Lung Cancer (NSCLC).
ErinMarie O Kimbrough, Julian A Marin-Acevedo, Leylah M Drusbosky, Ariana Mooradian, Yujie Zhao
Cancers. 2024-06-27
Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.
Siddharth M Patel, Yu Mi Kang, KyungAh Im, Brendon L Neuen, Stefan D Anker
Circulation. 2024-06-04

Authored Content

Patient referralJanuary 2022
Provider ProfileJanuary 2022

Press Mentions

New Data Showing That Transgene and NEC’s Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses Against Tumors Presented at AACR 2023April 18th, 2023
Transgene Presented Additional Phase I Data with TG4050 (Myvac® Platform) at ASCO 2022June 6th, 2022
Risk Factors for LAAT in Patients with Atrial FibrillationMay 3rd, 2022
Join now to see all

Professional Memberships

Other Languages

Chinese (Mandarin)